Literature DB >> 19232771

Accuracy of pathological diagnosis of mesothelioma cases in Japan: clinicopathological analysis of 382 cases.

Yukio Takeshima1, Kouki Inai, Vishwa Jeet Amatya, Kenichi Gemba, Keisuke Aoe, Nobukazu Fujimoto, Katsuya Kato, Takumi Kishimoto.   

Abstract

Incidences of mesothelioma are on the rise in Japan. However, the accurate frequency of mesothelioma occurrence is still unknown. The aim of this study is to clarify the accuracy of pathological diagnosis of mesothelioma. Among the 2742 mesothelioma death cases extracted from the document "Vital Statistics of Japan" for 2003-2005, pathological materials were obtained for 382 cases. After these materials were reviewed and immunohistochemical analyses were conducted, mesothelioma was diagnosed by discussions based on clinical and radiological information. Sixty-five cases (17.0%) were categorized as "definitely not/unlikely" mesotheliomas, and 273 cases (71.5%) were categorized as "probable/definite" mesotheliomas. The percentage of "probable/definite" pleural and peritoneal mesothelioma cases in males was 74.3% and 87.5%, respectively, and that of pleural cases in females was 59.2%; however, the percentage of "probable/definite" peritoneal cases in females was only 22.2%. These results suggest that the diagnostic accuracy of mesothelioma is relatively low in females and in cases of peritoneal and sarcomatoid subtype mesotheliomas; furthermore, approximately 15% of cases of deaths due to mesothelioma in Japan are diagnostically suspicious.

Entities:  

Mesh:

Year:  2009        PMID: 19232771     DOI: 10.1016/j.lungcan.2009.01.011

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  9 in total

1.  Clinical investigation of malignant mesothelioma in Japan.

Authors:  Nobukazu Fujimoto; Keisuke Aoe; Kenichi Gemba; Katsuya Kato; Koichi Yamazaki; Takumi Kishimoto
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-06       Impact factor: 4.553

2.  Malignant pleural mesothelioma in Italy.

Authors:  Claudio Bianchi; Tommaso Bianchi
Journal:  Indian J Occup Environ Med       Date:  2009-08

3.  Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry.

Authors:  Helmut P Sandeck; Oluf D Røe; Kristina Kjærheim; Helena Willén; Erik Larsson
Journal:  Diagn Pathol       Date:  2010-07-06       Impact factor: 2.644

4.  Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease.

Authors:  T Chernova; X M Sun; I R Powley; S Galavotti; S Grosso; F A Murphy; G J Miles; L Cresswell; A V Antonov; J Bennett; A Nakas; D Dinsdale; K Cain; M Bushell; A E Willis; M MacFarlane
Journal:  Cell Death Differ       Date:  2016-02-19       Impact factor: 15.828

5.  Echocardiographic characteristics of primary malignant pericardial mesothelioma and outcomes analysis: a retrospective study.

Authors:  Lingyun Kong; Ziwang Li; Jingrui Wang; Xiuzhang Lv
Journal:  Cardiovasc Ultrasound       Date:  2018-04-26       Impact factor: 2.062

6.  Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma.

Authors:  J Yamamoto; K Ohnuma; R Hatano; T Okamoto; E Komiya; H Yamazaki; S Iwata; N H Dang; K Aoe; T Kishimoto; T Yamada; C Morimoto
Journal:  Br J Cancer       Date:  2014-04-17       Impact factor: 7.640

7.  Establishment of anti-mesothelioma monoclonal antibodies.

Authors:  Natsuko Mizutani; Masaaki Abe; Shuji Matsuoka; Kazunori Kajino; Midori Wakiya; Naomi Ohtsuji; Ryo Hatano; Chikao Morimoto; Okio Hino
Journal:  BMC Res Notes       Date:  2016-06-24

8.  Asbestos-related diseases in mineworkers: a clinicopathological study.

Authors:  Ntombizodwa Ndlovu; David Rees; Jill Murray; Naseema Vorajee; Guy Richards; Jim teWaterNaude
Journal:  ERJ Open Res       Date:  2017-08-25

9.  Burden of Mesothelioma Deaths by National Income Category: Current Status and Future Implications.

Authors:  Odgerel Chimed-Ochir; Diana Arachi; Tim Driscoll; Ro-Ting Lin; Jukka Takala; Ken Takahashi
Journal:  Int J Environ Res Public Health       Date:  2020-09-21       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.